Comparison · NCT02169284-sae
Group I (Erlotinib Hydrochloride) vs Group II (Placebo): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group I (Erlotinib Hydrochloride) vs Group II (Placebo): serious adverse events. Trial comparisons, record NCT02169284-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02169284-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0417 | 0.00739 | 0.202 | wilson | |
| Risk in group 2 | 0.154 | 0.0433 | 0.422 | wilson | |
| Risk difference, group 1 minus group 2 | -0.112 | -0.383 | 0.0829 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.271 | 0.0271 | 2.71 | log | |
| Odds ratio, group 1 over group 2 | 0.239 | 0.0195 | 2.93 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Group I (Erlotinib Hydrochloride) than on Group II (Placebo) | 8.91 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group I (Erlotinib Hydrochloride) | Participants receive erlotinib hydrochloride PO QD on days 1, 8, and 15. Participants then undergo TURBT or cystectomy on day 16. | 1 | 24 | EG000 |
| Group 2 | Group II (Placebo) | Participants receive placebo PO QD on days 1, 8, and 15. Participants then undergo TURBT or cystectomy on day 16. | 2 | 13 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- up to 9 weeks
Source ClinicalTrials.gov
Trial
- Title
- Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
- NCT number
- NCT02169284
- Phases
- PHASE2
- Conditions
- Bladder Carcinoma, Recurrent Bladder Carcinoma
- Interventions
- Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Placebo, Quality-of-Life Assessment, Therapeutic Conventional Surgery
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2020-07-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02169284?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02169284-sae